Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SVENSKA HANDELSBANKEN-A SHS. We currently have 4 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
SVENSKA HANDELSBANKEN-A SHS
SVENSKA HANDELSBANKEN-A SHS
Net interest income definitely bottoming out...
08 Feb 17
Svenska Handelsbanken released this morning its Q4 16 earnings results. Total income was SEK10.12bn, 1.5% higher than expectations with the beat being high quality as both net interest income and fees/commissions were higher than consensus forecasts. The flip side of the coin was total expenses at SEK4.61bn which were 2% higher than expectations. Loan losses on their side, at SEK832m, were SEK367m higher than expectations. All in all, the operating profit at SEK4.7bn is 6% short of expectations. The CET1 ratio at 25.1% is 110bp higher qoq, well above the regulatory requirements (at 21.3%) and roughly 100-300bp above management’s target (22-24%). Despite this high level of capital, the dividend at SEK5 is below consensus expectations (at SEK5.58).
Reassuring net interest income
20 Oct 16
Handelsbanken (SHB) was the first Nordic bank to release its Q3 16 earnings. With SEK10.47bn, total income is 4% higher than expectations. With expenses in line with expectations but much higher loan losses, profit before tax is just 1% above consensus, at SEK5.69bn. In terms of solvency, the CET1 ratio is 24% versus 23% in Q2 16.
Mixed news on the Q1 16 earnings release
20 Apr 16
Svenska Handelsbanken (SHB) released its Q1 16 earnings this morning. Revenues are in line with expectations but driven by non-core revenues. Expenses, excluding one-off items, are a bit better than expected and loan losses are much better than expected. All in all, reported operating profit is 6% lower than expectations at SEK4.97bn (versus SEK5.26bn). The CET1 ratio came in at a high 22.7% (versus 21.2% at the end of last quarter). With mixed news, the share price at the opening is therefore almost flat compared to yesterday’s closing.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.